We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Lyxr $ Frn | LSE:BUOY | London | Exchange Traded Fund |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 101.565 | 101.46 | 101.67 | - | 0 | 01:00:00 |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 22/11/2017 09:55 | TSXV:LG David Lenigas, Co-Chairman of LGC added, "On behalf of LGC and in recognition of yesterday's announcement by our Swiss strategic partner Creso Pharma, we applaud Creso's achievement in expanding its global footprint and entering the very sizable Chinese market." | cpap man | |
| 21/11/2017 15:50 | TSXV:LG LGC Capital Increases Size of Oversubscribed Private Placement Financing and Provides Update on Quebec Cannabis Investment MONTREAL, Nov. 21, 2017 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) ("LGC") is pleased to provide an update on LGC's previously-announced private placement financing and its proposed investment in new Quebec cannabis-focused AAA Trichomes. Private Placement Financing – Over Subscribed LGC is pleased to announce that in light of very heavy demand, it has decided to increase the maximum amount of its previously-announced private placement by 62% to CDN $3.25 million. On November 16, 2017, LGC announced a private placement of units in a maximum amount of CDN $2 million. Closing of the private placement is scheduled to take place this week. LGC has increased the financing amount to pursue further cannabis growth opportunities globally currently under consideration. AAA Trichomes – Quebec, Canada The previously-announced closing date for the proposed transaction with Tricho-Med Corporation, doing business as AAA Trichomes ("AAA Trichomes"), has been revised from November 24 to November 29, 2017. As announced on October 31, 2017, LGC signed an option to acquire a 49% interest in Quebec-based AAA Trichomes, plus a 5% royalty on its net sales. AAA Trichomes is planning to build a significant new cannabis processing facility in the Province of Quebec. All parties are working diligently and LGC is pleased with the progress made to date on this proposed transaction. The parties have mutually agreed to extend the deal closing date to allow for completion of the due diligence review and obtaining the necessary regulatory approvals, including that of the TSX Venture Exchange. John McMullen, CEO of LGC states, "We are pleased with the size and scope of the transactions currently happening in the cannabis sector and we believe that we are building the next investment opportunity with our international business model. This is evident by the solid uptake in this current private placement. We have received interest and orders from sizable global institutions and high net worth individuals, who I believe will be great partners as we move to the next level as a cannabis investment company. These new funds are targeted at growing the existing investment portfolio and seeking new cannabis opportunities globally." David Lenigas, Co-Chairman of LGC added, "On behalf of LGC and in recognition of yesterday's announcement by our Swiss strategic partner Creso Pharma, we applaud Creso's achievement in expanding its global footprint and entering the very sizable Chinese market." hxxp://www.skynews.c As previously announced, LGC and Creso Pharma Limited have entered into a letter of intent for a strategic alliance for the purpose of establishing a vertically-integrate About AAA Trichomes: AAA Trichomes was incorporated in 2014 with the objective of becoming a manufacturer and distributor of cannabis products in Canada with an initial focus on the Quebec market. Since November 2016, AAA Trichomes has been in the final review stage with Health Canada for the processing of its application to become a licensed producer under the Access to Cannabis for Medical Purposes Regulations. About LGC Capital Ltd.: www.lgc-capital.com LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC is a diversified investment company with core holdings in businesses that provide shareholders with exposure to a diverse range of high-growth businesses, products and services. To date, LGC has entered into agreements for investments in private cannabis operations in South Africa, Australia and Canada. LGC also has a joint venture with AfriAg (Pty) Ltd. to grow and distribute medical and recreational cannabis products in the southern African region for export to regulated and certified end users around the world, and a strategic alliance with Creso Pharma Limited for the creation of a vertically-integrate Information Relating to AAA Trichomes and Creso: All information contained in this press release relating to AAA Trichomes and Creso has been provided to LGC by each, respectively. LGC has relied upon this information without having made independent inquiries as to its accuracy or completeness and assumes no responsibility for any inaccuracy or incompleteness of such information. | cpap man | |
| 20/11/2017 18:45 | TSXV:LG "ON FIRE" | cpap man | |
| 08/11/2017 12:55 | NASDAQ:GALT Galectin Therapeutics Reports 2017 Third Quarter Financial Results and Provides Business Update 07/11/2017 1:15pm GlobeNewswire Inc. Galectin Therapeutics Inc. (MM) (NASDAQ:GALT) Intraday Stock Chart Today : Wednesday 8 November 2017 Click Here for more Galectin Therapeutics Inc. (MM) Charts. All 52 weeks of infusions and 100% of the doses have been administered in the NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial Top Line Results of NASH-CX Phase 2b Clinical Trial Expected to be announced in early December 2017 Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended September 30, 2017. These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. “All of the patients in our NASH Cirrhosis, NASH-CX Phase 2b Clinical Trial have completed all 52 weeks of infusions and 100% of the doses have been administered,” said Peter G. Traber, M.D., president, chief executive officer and chief medical officer of Galectin Therapeutics. “The dropout rate was well below expectations, with 151 subjects out of the 162 enrolled having completed the full trial regimen. The data will be compiled and analyzed in expectation that we will meet our original target of reporting top line data in early December 2017.” Expected Upcoming Milestones Company remains on track to report top line data from the NASH-CX Phase 2b Clinical Trial in December 2017. Summary of Key Development Programs and Updates Company is funded through February 2018, which is sufficient to report top line data of the NASH-CX Phase 2b Clinical Trial. Dr. Peter G. Traber, M.D., the Company’s president, chief executive officer and chief medical officer was Chair of the Conference for NASH Summit Europe 2017, an industry nonalcoholic steatohepatitis (NASH) drug development forum that was held in Frankfurt, Germany from October 10-12, 2017. The Company received a Decision to Grant from the Chinese Patent Office for its patent application for “Composition of Novel Carbohydrate Drug for Treatment of Human Diseases,” which, when issued, will extend composition of matter coverage of the Company's lead compound, GR-MD-02, to China, where the prevalence of fatty liver disease has approximately doubled over the past two decades, with around 15% of the population experiencing NASH. Financial Results For the three months ended September 30, 2017, the Company reported a net loss applicable to common stockholders of $4.7 million, or $0.13 per share, compared with a net loss applicable to common stockholders of $4.5 million, or $0.16 per share, for the three months ended September 30, 2016. The decrease is largely due to lower general and administrative expenses and to lower stock compensation expenses. Research and development expense for the three months ended September 30, 2017 was $3.5 million, compared with $3.3 million for the three months ended September 30, 2016. The increase primarily is primarily related to higher pre-clinical and drug manufacturing expenses. General and administrative expense for quarter was approximately $900,000, compared with $1.2 million for the prior year, with the decrease being primarily related to lower investor relations and non-cash stock compensation expenses. As of September 30, 2017, the Company had $7.0 million of non-restricted cash and cash equivalents. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through December 31, 2017. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeu | cpap man | |
| 02/11/2017 16:10 | Uranium Superstar Goes All-In On Impending Nickel Crunch Mike Beck is surgical when it comes to investing. Utilizing a top-down approach, he first performs detailed analysis on a given commodity. If a supply crunch is imminent, he will hunt down the cheapest projects and acquire them. He believes that prices must reflect scarcity. In early 2005, Mike identified the gaping supply crunch in uranium. Prices had been beaten, but a decline in supply was on the horizon. Accompanied by extraordinary lead times to new production, Mike saw an opportunity and began consolidating assets with his partner Stephen Dattels. UraMin was birthed in 2005, and soon had developing mining projects in Namibia, South Africa, and the Central African Republic—to the tune of roughly 170 million pounds of uranium. Time proved Beck’s thesis was dead on. Over the next two years the Uranium price would sky-rocket, from $20.54/lb in January 2005 to $136.22/lb by June of 2007. UraMin did not discover anything. Mike simply picked-up depressed assets for pennies on the dollar, most of which were low-grade deposits. His market acumen would soon land him in the middle of a full-fledged bidding war. The company listed on the TSX in December 2006. A property package stiched together by Mike’s group for a mere US$4 M was acquired by French uranium company Areva in June of 2007— for US$2.5-billion. Since then, Mike has kept a fairly low profile, researching ideas and searching for his next thesis. And it appears he found it. Beck is convinced that this next market sensation will not just trump uranium’s move a decade ago; he believes this could be the biggest move in a commodity since the invention of tin foil in the early 1900s! When the electric vehicle revolution blipped on his radar, he immersed himself in the numbers, contacting his vast network of industry insiders and institutional analysts for information. After literally years of research, he readied for his next big trade. Different commodity, yet the plan remains consistent: avoid exploration risk by identifying a known deposit which is out of favor, but poised to come roaring back. Mike’s EV thesis can be summed up as follows: – Governments around the world are cracking down on emissions, which will lead to a drastic decrease in conventional vehicles sales – Electric vehicle batteries are becoming cheaper and cheaper. In fact, by 2024, it will be cheaper to own an EV than an ICE-vehicle in the EU, United States, and China. – EVs are faster and easier to build than internal combustion engines. EV factories have half the footprint, thus require half the capital investment. They are also 30% more efficient, and can easily be scaled and reconfigured to support demand. In short, it is inevitable that the EV market will overtake the personal vehicle market. Currently, lithium, cobalt, and nickel are the key ingredients in the lithium-ion battery. Mike found the best way to leverage each in the coming supply crunch. Mike’s Lithium Play – LSC Lithium Corporation (TSXV:LSC) LSC Lithium is the owner of the largest lithium land package in northern Argentina, arguably the largest in the world. Located in the prolific “Lithium Triangle” in South America, the company has amassed a portfolio of prospective lithium rich salars—vast salt flats that contain most of the world’s lithium. This includes six major development properties: Pozuelos (Salta), Pastos Grandes (Salta), Salinas Grandes (Salta), Salinas Grandes (Jujuy), Rio Grande (Salta) and Jama (Jujuy). The acreage is on high-quality salars in the provinces of Salta and Jujuy, and is being fast tracked to production. LSC Lithium was formed in 2016, and listed on TSX Venture in February 2017 via RTO. In conjunction with the RTO, LSC raised $40 million, and recently closed another $20 million. The company is currently working to develop a Preliminary Economic Assessment (PEA) and define mineral resource estimates for its flagship properties. The company is spending around $1M per week to advance their lithium projects towards a resource. This is a serious operation, backed by lots of capital and serious brain power. In a recent new release, the company announced it was reviewing strategic alternatives, which is industry talk for entertaining acquisition offers. A take-out in the near future would not surprise us; LSC is on the exact same trajectory as UraMin. Mike’s Cobalt Play – Cobalt 27 Capital Corp. (TSXV:KBLT, FSE: 27O) Cobalt makes an incredibly compelling case for investors. Global production is just 100,000 tons per annum. Demand is expected to exceed production by a factor of 3X within the next decade. The problem though, is that cobalt is primarily produced as a by product of copper and nickel production. As such, getting exposure to the inevitable run in cobalt is not so simple. Mike could not find an actual asset to play cobalt, so instead he bought the physical commodity itself – and a lot of it. In 2017, Mike’s group became the second largest buyer of physical cobalt in the world. They then took that hoard and put it into a company called Cobalt 27, a pure-play investment that offers direct leverage to cobalt. Cobalt 27, which IPO’d in June of this year, was the largest resource IPO since Robert Friedland took Ivanhoe public in 2012. It is underpinned by C$170 million of physical cobalt, but is also looking to grow through streaming and royalty acquisitions. The company currently holds 7 cobalt royalties. Cobalt 27 will track the cobalt price as it continues to rise. Adding additional streams to the portfolio will provide an asymmetrical reward profile for investors. And since Mike believes that Cobalt will blow through $100 per pound, it’s no surprise he sees this as a great way to play. Mike’s Nickel Play – Giga Metals Corporation (TSXV:GIGA, FSE: BRR2) Lithium and cobalt have already seen their prices soar, however, people are only now beginning to realize the impact that the EV revolution will have on the nickel market. Nickel is at multi-year lows, providing an ideal entry point for the contrarians of the world. The current nickel market represents 2.25 million tonnes per annum. The market is beginning to bifurcate, however, only nickel sulphide deposits can produce the class 1 nickel that is suitable for batteries. Class 1 nickel represents just 50% of current nickel production. Using conservative EV adoption rates, the demand for class 1 nickel is expected to increase 3-fold in the coming decade. That is a lot of catch up required for nickel production and a massive opportunity for investors! In Giga Metals, Mike found the 2nd Largest undeveloped nickel-cobalt sulphide deposit in the world! The 100%-owned Turnagain Project contains a resource of 1.8 billion tonnes, which is based on less than 25% of the prospective geology, meaning there is significant exploration upside with minimal drilling. Turnagain has the potential to become the world’s largest undeveloped nickel cobalt-sulphide deposit, and one of the largest cobalt producers outside of the Congo. Giga plans on completing an internal scoping study and undertaking additional exploration and metallurgical work on the Turnagain Project. This will allow them to reoptimize the project – by concentrating on the high-grade, the company can significantly reduce capex. The optionality on Turnagain is significant. We cannot forget that the market once valued the company at C$150 million when nickel prices were rising: Still not convinced about the value yet to be unlocked here? Giga Metals has 5 times the amount of nickel reserves as Robert Friedland’s Clean TeQ Holdings Limited (ASX:CLQ), yet has a market cap 2% the size! Mike’s Next Nickel Play – Mustang Minerals Corp (TSXV:MUM) Worried you missed the boat on Giga Metals? We’d beg to differ, but here is Mike’s next, lesser known nickel play – Mustang Minerals (TSXV:MUM). It has the same storyline as Giga, a completely mispriced and forgotten asset in two near-surface open-pit deposits, Mayville (Cu-Ni-PGM), and Makwa (Ni-Cu-PGM-Co). The projects have had C$40-50 million in past exploration and development expenditures, with PEA level economics. Like Giga, the economics were calculated in a more favorable nickel environment – at one point in time Mustang boasted a ~C$100 million market cap: Mustang’s projects are viable in the near future as capex is more digestible at C$207 million. Mining will be simple with low-cost extraction and processing methods. The pits will be shovel mined and ore hauled with conventional trucks. The company plans on optimizing several aspects of the current plan, including resource definition, improvement of metallurgical recoveries, and defining high-grade depth extensions to deposits. Like Giga, there is also considerable exploration upside in prospective geology. Both stocks have already performed incredibly well in 2017, but the nickel narrative is just beginning to play out. We expect to see a greater run-up before some very large, sophisticated pools of investment capital take positions to finance these emerging stories. Nickel will be in deficit in the coming years; we believe Giga and Mustang are the best vehicles out there to lever the bet on nickel. | cpap man | |
| 31/10/2017 14:00 | TSXV:LG LGC Capital Signs First Canadian Cannabis Deal In Quebec MONTREAL, Oct. 31, 2017 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) ("LGC") is pleased to announce that it has signed an option with Quebec based Tricho-Med Corporation, doing business as AAA Trichomes (AAA Trichomes) to acquire a 49% interest (plus a 5% royalty) in a new cannabis processing facility to be built in the Province of Quebec. Subject to permitting, the AAA Trichomes processing facility will be one of the first enclosed multi-level medical cannabis producers in Quebec. Trichomes is scheduled to start operations in 2019 with an initial annual production rate of over 2,500 kilograms reaching a planned production rate of over 20,000 kilograms by 2021. "This is LGC's first deal directly in the Canadian cannabis sector and hopefully the first of a number of Canadian deals the Company is looking at taking a strategic investment." Commented John McMullen, LGC Capital's CEO. "This deal is on the back of our recent investment in Little Green Pharma, one of Australia's fully licensed and permitted medical cannabis companies that is moving rapidly towards planting its first commercial crop (/or - has just planted its first commercial crop). We are also progressing well with our due diligence process on our potential investment in South Africa's House of Hemp, having now completed 3 months of the due diligence on this exciting business." Under the terms of the exclusive option agreement, LGC plans to fund the building of the facility by way of a $4 million fully secured convertible debenture bearing interest at the rate of 10% per annum. Upon the facility being approved for cannabis cultivation and production, the debenture will automatically be converted to a 49% holding in the issued common share capital of Trichomes as well as a 5% royalty on all net sales of cannabis products. AAA Trichomes was incorporated in 2014 with the objective of becoming a manufacturer and distributor of cannabis products in Canada with an initial focus on Quebec market. Since November 2016, AAA Trichomes has been in the final review stage with Health Canada for the processing of its application to become a licensed producer under the Access to Cannabis for Medical Purposes Regulations. The critical path in this transaction calls for due diligence to be completed by November 15th with a closing on an initial funding of $2 Million to take place on November 24th of this year. Conditions precedent to closing include, inter alia, execution and delivery of all definitive agreements relating to the convertible debentures, the net sales royalty and registration of securities against the assets of the Borrower. LGC plans to fund this investment over the construction period from current cash reserves and from Institutional debt. Closing is also conditional upon LGC having obtained all requisite regulatory and TSX Venture Exchange approvals. About LGC (www.lgc-capital.com LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services. | cpap man | |
| 12/10/2017 15:40 | TSXV:LG LGC Capital Completes Acquisition of Initial Strategic Interest in Licenced Australian Medical Cannabis Company - Little Gree... MONTREAL, Oct. 12, 2017 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) ("LGC") is pleased to announce that it has today completed the acquisition of stage one of its strategic interest in licenced Australian Medical Cannabis company Habi Pharma Pty Ltd of Perth, Australia, doing business as "Little Green Pharma", as announced on September 26, 2017 and October 5, 2017. On October 5, 2017, the Company announced that the TSX Venture Exchange had authorized LGC to proceed to the closing of the transaction and this transaction has now been completed. At the closing, LGC subscribed for 2,161,091 shares of Little Green Pharma, representing an initial 4.99% of its issued and outstanding shares. As consideration for the shares, LGC paid AUD $432,218 and issued 5,660,000 LGC common shares to Little Green Pharma at a deemed issue price of $0.11 per share. LGC, subject to certain Australian regulatory and other approvals, can now move towards increasing its interest in Little Green Pharma up to 19.03%. About Little Green Pharma: Little Green Pharma is one of the few companies in Australia to be granted a licence to cultivate and produce Medical Cannabis within Australia. Little Green Pharma (www.lgpharma.com.au The Australian Medical Cannabis Market: Little Green Pharma has advised LGC that Australia passed federal legislation in 2016 aimed at permitting the use of Medicinal Cannabis via a tightly-controlled licensed medical prescription system. In March 2016, The White Paper, entitled Medicinal Cannabis in Australia: Science, Regulation & Industry, was developed by the University of Sydney Business School's Community Placement Program. Its publication followed the news that the Australian Government would shortly allow the cultivation of cannabis in Australia for medical or scientific purposes. As the first-ever White Paper that analyses the medicinal cannabis industry in Australia, the paper examines international experiences and approaches, supply chain economics, quantities of cannabis required and potential regulatory dynamics. It also serves as a framework for the industry to commence engaging key stakeholders such as the Australian Government and the medical community. The University of Sydney summary of the White Paper can be viewed via the below link: hxxp://sydney.edu.au The White paper can be viewed at: hxxp://mgcpharma.com Highlights of the White Paper: Australia would need to produce 8,000 kg of medicinal cannabis per year to service the existing market. Australian market currently estimated to be worth AUD $100 million to AUD $150 million per annum, and is likely to grow significantly in the next decade. Medical Cannabis has the potential to help tens of thousands of patients suffering from a wide range of medical conditions such as Multiple Sclerosis, Epilepsy, Cancer, and Severe and Chronic Pain. Up to 51,000 square metres of greenhouse space - almost three times the size of the Sydney Cricket Ground - would be needed to produce the amount of cannabis required to meet demand. Further investment stages of the Little Green Pharma acquisition: As previously announced, the subscription agreement between LGC and Little Green Pharma provides that subject to the issuance by Little Green Pharma of shares to various third parties, LGC will subscribe for a further 752,937 shares of Little Green Pharma for cash consideration of AUD $150,587, so as to maintain its shareholding in Little Green Pharma of 4.99%. In addition, subject to certain Australian regulatory approvals, which are currently in progress, and subject to approval by Little Green Pharma in its sole discretion, LGC may further subscribe, at its option, for additional shares of Little Green Pharma in order to increase its shareholding to a maximum of 19.03%. In the event that this option is exercised, LGC will subscribe for a maximum of 4,585,972 shares of Little Green Pharma for maximum cash consideration of AUD $917,194. Note: On October 11, 2017, the Bank of Canada's daily average exchange rate for the Australian dollar was AUD $1.00 = CAD $0.9728. About LGC (www.lgc-capital.com LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services. | cpap man | |
| 11/10/2017 15:40 | TSXV:LG LGC Capital Announces Merchant Banking Division and New Opportunity MONTREAL, Oct. 10, 2017 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) ("LGC") is pleased to announce that it has formally established a merchant banking division within its business, which will pursue global high-yield investment opportunities. This new division will run parallel with and will not deter efforts from LGC's cannabis investments and the pursuit of additional cannabis opportunities. "The merchant banking side of LGC Capital is an outstanding opportunity for the company and its shareholders," commented John McMullen, CEO of LGC. "I will remain 100% committed and focused on building our global cannabis footprint, while LGC's Co-Chairman Mazen Haddad will head up this division and continue to pursue large high-yield investment opportunities for LGC. Mazen has a successful history and track record with sourcing funding and executing these types of transactions." As part of this announcement, LGC announces that it has entered into an agreement with a Toronto-based investment firm whereby LGC will guarantee repayment by Etea Sicurezza Group Ltd ("Etea Sicurezza") of notes issued by Etea Sicurezza in an aggregate principal amount of USD $1,000,000 ("Notes"). The Notes have a term of two years, bear interest at a rate equal to LIBOR + 8%, and are secured by the assets of Etea Sicurezza and by a pledge of shares by Etea Sicurezza's principal shareholder. As consideration for the guarantee, Etea Sicurezza will issue shares to LGC representing 3% of its outstanding shares and pay an annual cash fee to LGC. LGC and Etea Sicurezza are also negotiating a transaction whereby LGC will acquire all of the outstanding shares of Etea Sicurezza and distribute a portion of the shares to LGC's shareholders, with the intention of Etea Sicurezza becoming a public listed company. At such time, if any, as LGC and Etea Sicurezza enter into an agreement, LGC will issue a press release announcing the details of the transaction. Based in London, England, Etea Sicurezza (www.eteasicurezzagr "I have known the founder and principal of Etea Sicurezza for a number of years," stated Mazen Haddad, Co-Chairman of LGC. "He approached me on this situation and I jumped on it knowing that LGC can help and that this opportunity can add significant value for our shareholders." Under the guarantee, LGC will be required to pay all of Etea Sicurezza's obligations under the Notes if Etea Sicurezza does not make payment to the holders of the Notes and if AIP sends a demand letter to LGC. If LGC repays the Notes, it will be subrogated in the rights of the holders of the Notes. In the event that LGC is required to pay under the guarantee, it has the option to pay all or part of the amount through the issuance of LGC shares at a price per share equal to 80% of the weighted average trading price of LGC's shares on the TSX Venture Exchange, or such other stock exchange on which LGC's shares then principally trade, for the five trading days immediately preceding the date of issuance of the shares. The guarantee and related issuance of shares by LGC are subject to approval by the TSX Venture Exchange. LGC Merchant Banking has begun the approval process but cannot give any assurance that it will be able to obtain such approval. In addition, LGC cannot give any assurance that it will conclude a further transaction with Etea Sicurezza as described in this press release. About LGC Capital (hxxp://www.lgc-capi LGC Capital Ltd.'s (TSXV: LG) mission is to invest into global high-yield diversified businesses. LGC's flagship project is its partnership with AfriAg (Pty) Ltd. and South Africa's House of Hemp to grow, cultivate and distribute medical-grade cannabis from its 40,000 m2 facility located in Block D of the Dube Tradeport's Agrizone Complex. This greenhouse is the most eco-friendly and high tech agricultural facility in Africa. | cpap man | |
| 10/10/2017 16:50 | TSXV:LG TSXV:LG could well soon trade north of CAD$1.00 | cpap man | |
| 10/10/2017 16:13 | TSXV:LG WOW TSXV:LG breaking out aggressively now chart wise! | cpap man | |
| 07/10/2017 11:35 | TSXV:LG Are TSXV:LG on the verge of a chart break out? | cpap man | |
| 07/10/2017 11:33 | TSXV:LG TSXV:REG TSXV: RYR TSX:LYD TSXV:KZD | cpap man | |
| 06/10/2017 18:21 | Kincora Copper (CVE:KCC, FRA:BS4B) – On The Cusp Of A Major Copper Discovery In Mongolia Current Price: C$0.34 Shares Outstanding: 68.7 million (post-EBRD financing) Market Capitalization: C$23.5 million Cash: ~C$5.92 million (post-EBRD financing) A copper discovery of Kincora’s proposed magnitude will significantly rewards investors. One example of an explosive copper discovery is Camino Minerals (TSXV:COR, Mkt Cap: $27M). When the company announced a 106 meter intercept of 1.3% Cu at the Los Chapitos Project in Peru, the stock sky-rocketed 26x from its low. SolGold (TSX:SOLG, Mkt Cap: $1.1B) is another recent case of a major copper discovery driving shareholder gains – 24x since January 2016. As we will find out, the company is analogous to Kincora Copper in many ways. Solgold was able to secure a foothold in a significantly mineralised but underexplored belt in Ecuador, when the jurisdiction was experiencing turmoil. A new government ushered in a more functioning bureaucratic system and investor sentiment began to rise. This is the phase Mongolia finds itself in today. Mongolia – The “Country of Blue Sky” Mongolia is once again open to mining. And its Kincora Copper, armed with Robert Friedland’s best acreage, that is currently drilling. The Democratic Party, solely responsible for running the country into the ground, has been removed. The Mongolian People’s Party now controls 85% of Parliament, wielding clear legislative power and authority. Their mandate from the get-go has been clear – turn the economy around. In support of the newly-elected government’s Economic Recovery Plan, the IMF has approved a three-year, $434 million loan for Mongolia as part of a broader $5.5 billion financing package. In terms of GDP, this is the fourth-largest package in IMF history, stressing the international community’s commitment to Mongolia’s future economic success. A large part of this restructuring and IMG financing hinges on the reform of the mining sector, which constitutes a significant part of Mongolia’s economy. In this new political cycle, we are seeing the old guard, politicians who have been in place since the Soviet era, being replaced by the next generation. This new group has been educated in Western institutions and has extensive work experience and relationships in the international arena. Mongolia is very much like China during its transitionary phase 15-20 years ago, but the change will occur much faster given the demography and size of the population. All of these factors will contribute to a sustainable cycle, one that will last much longer than previous political cycles. These developments are so significant, for the first time since 2012, Rio Tinto is once again drilling and revisiting opportunities in the belt. Mongolia saw significant exploration between 1996-2006, which included discovery of the Oyu Tolgoi deposit, the largest project in Mongolian history. Regional exploration continued through 2009 and included the joint-venture between Robert Friedland’s Ivanhoe (now Turquoise Hill Resources) and BHP Billiton. Robert Friedland was responsible for the lion’s share of exploration, and at Ivanhoe’s peak, it owned a portfolio of assets encompassing over 126,000 km2 of prospective land. The geological data collected gave incredible understanding of the regional geology and controls on mineralization. When the windfall tax was announced in May 2006, Ivanhoe released the majority of its regional landholdings. Then, the tax was repealed in August 2009. The best acreage was picked up yet again; this time by IBEX, an entity indirectly controlled by Robert Friedland’s High Power Exploration Inc. Kincora Copper Emerges As The Go-To Play In July 2011, a company called Kincora Copper came on the scene. Kincora began consolidating the area. The company’s first transaction was picking up the Bronze Fox license, originally part of Ivanhoe’s portfolio. In 2005, Bronze Fox was designated as a high priority target for large-scale porphyry and skarn copper mineralization, alongside existing deposit, Oyu Tolgoi. Previous drilling included 72 holes for over 12,000 metres, confirming continuous mineralization on a 9-kilometer strike. Drilling also saw a large low-grade copper-gold feature from surface to depth (returning between 0.4% and 0.9% copper equivalent). In 2012, Kincora acquired Golden Grouse LLC, to consolidate the rest of the original “Ivanhoe” Exploration on the Bronze Fox and Western license border returned over 800 meters of 0.40% copper equivalent, including 37 meters at over 1% copper equivalent. Furthermore, 9 of the 15 holes drilled in 2012 at the Tourmaline Hills gold prospect in the Western license returned intervals of at least 1 g/t Au, up to 7.7 g/t Au, often with elevated copper values. In Q1 2016, Kincora secured a new exploration license, Ulaan Khudag (Red Well), located 15 kilometers along the mineralized trend from the Rio Tinto controlled, Oyu Tolgoi project. An identified contact continues to the eastern and western sections of the license, the margin just to the east returning a previous 2% copper and 0.25bg/t gold sample with anomalous values also to the west. In May 2016, Kincora announced its agreement with IBEX, resulting in Kincora more than tripling its landholding in the Southern Gobi copper belt, totaling over 1,500 km2. Robert Friedland currently controls 9.62% of Kincora. Kincora has two drill ready targets, each analogous to existing large-scale mines in the belt. East TS is a confirmed “brownfield TS, a $1 billion project owned by Mongolyn Alt (MAK) Corp., is home to a total proven reserve of 230 million tonnes of primary sulphide ores, equivalent to 1.5 million tonnes of copper and 60,000 tonnes of molybdenum. The property also has 15 million tonnes of oxide ores sitting as a cap over the sulphide. The mine commenced in 2012 and is now engaged in soil stripping. The production capacity of the open-pit is 13 million tpa ores to produce 290,000 tpa copper concentrates and 4,000 tpa molybdenum concentrates. Bayan Tal is an “Oyu Tolgoi” style target, which of course is Turquoise Hill and Rio Tino’s US$14 billion mega project, home to reserves of 32.4 million tonnes of copper, 34.0 million ounces of gold, 262.2 million ounces of silver, and 12,900 tonnes of molybdenum. Bayan Tal has confirmed Devonian “Oyu Tolgoi style” stratigraphy at the Bayan Tal Igneous Complex, and includes an 18 meter of 0.66% CuEq drill hole on the margin of the interpreted system. Bayan Tal is one of the most important untested complexes in the Southern Mongolian belt, with multiple drill ready targets. Kincora closed a $4.52 million in financing in August 2017, and recently announced the second tranche, a $1.4 million investment by the European Bank for Reconstruction and Development (EBRD), for a total of $5.92 million. Kincora is currently drilling the East TS target. The maiden RC and diamond drill program is comprised of 2,870 metres, targeting a depth of less than 265 m depth for 12 holes. It is proposed that during a second phase, Kincora will undertake infill geophysics and a follow-on 5,000-metre drill program. Post IBEX transaction, copper experts who have been credited with multiple tier-1 discoveries have joined Kincora’s team. The company has implemented an exploration strategy that replicates the systematic approach that was successfully applied in discovering similar high-impact gold-copper porphyrys. In addition to the mentioned targets, Kincora is concurrently working on the integration of ground magnetics, detailed mapping, regional and local geochemistry for the purpose to advance a portfolio of ranked exploration targets across the district. The market is ready for the next generation of discoveries and Kincora is in the right place at the right time. Kincora is armed with extensive data, modern exploration techniques, and hard-hitting targets. The technical team has a tried and tested strategy of finding tier-1 discoveries, and are convinced Kincora is sitting on the biggest one yet. | cpap man | |
| 06/10/2017 17:15 | TSXV:LG LGC Capital Signs Definitive Agreement to Acquire Strategic Interest in Licenced Australian Medical Cannabis Company - Little... MONTREAL, Oct. 5, 2017 /CNW/ - LGC Capital Ltd. (TSXV: LG) ("LGC") is pleased to announce that it has entered into a definitive Subscription Agreement with licenced Australian Medical Cannabis company Habi Pharma Pty Ltd of Perth, Australia, doing business as "Little Green Pharma", for the acquisition of a strategic interest in Little Green Pharma, as announced on September 26, 2017. LGC is also pleased to announce that the TSX Venture Exchange has authorized LGC to proceed to the closing of the transaction, which is scheduled to take place on Tuesday, October 10, 2017. Little Green Pharma is one of the few licenced companies in Australia authorized to cultivate and produce Medical Cannabis within Australia. Little Green Pharma (www.lgpharma.com.au "The signing of a definitive Subscription Agreement and approval by the TSX Venture Exchange to acquire this strategic initial interest in Little Green Pharma in Australia are truly landmarks for LGC Capital, as we seek to expand the Company's global footprint in the fast-growing legalized medical cannabis industry" John McMullen, LGC's CEO commented. "We are pleased to be given the opportunity to be a key strategic shareholder of Little Green Pharma as it moves towards commercial production in the highly regulated and blue-chip Australian market. We are also very excited about Little Green Pharma's advanced patented technology." Fleta Solomon, Little Green Pharma's Managing Director, commented; "There is no doubt that LGC Capital is going to be a strong strategic partner as we expand the company and its opportunities." The details of LGC's agreement to invest in Little Green Pharma are as follows: At closing, LGC will subscribe for 2,161,091 shares of Little Green Pharma, representing an initial 4.99% of its issued and outstanding shares, by paying AUD $432,218 and issuing 5,660,000 LGC common shares to Little Green Pharma at a deemed issue price of $0.11 per share. Subject to the issuance by Little Green Pharma of shares to various third parties, LGC will subscribe for a further 752,937 shares of Little Green Pharma for cash consideration of AUD $150,587, so as to maintain its shareholding of 4.99% in Little Green Pharma. Subject to certain Australian regulatory approvals, which are currently in progress, and subject to approval by Little Green Pharma in its sole discretion, LGC may further subscribe, at its option, for additional shares of Little Green Pharma in order to increase its shareholding to a maximum of 19.03%. In the event that this option is exercised, LGC will subscribe for a maximum of 4,585,972 shares of Little Green Pharma for maximum cash consideration of AUD $917,194. Note: On October 4, 2017, the Bank of Canada's daily average exchange rate for the Australian dollar was AUD $1.00 = CAD $0.9802. Closing of the transaction with Little Green Pharma is subject to standard conditions. About LGC (www.lgc-capital.com LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services. | cpap man | |
| 27/9/2017 07:05 | TSXV:LG LGC Capital Signs Binding Term Sheet to Acquire Strategic Interest in Licenced Australian Medical Cannabis Company - Little G... 26/09/2017 8:17pm PR Newswire (Canada) Lgc Capital Ltd (TSXV:LG) Intraday Stock Chart Today : Wednesday 27 September 2017 Click Here for more Lgc Capital Ltd Charts. LGC Capital Ltd. Symbol: TSX-V: LG MONTREAL, Sept. 26, 2017 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) ("LGC") announces that it has entered into a binding term sheet with Habi Pharma Pty Ltd of Perth, Australia, doing business as "Little Green Pharma", which provides that LGC will acquire an initial strategic 4.99% interest in Little Green Pharma, one of the few licenced companies authorized to cultivate and produce Medical Cannabis within Australia. The binding term sheet provides that LGC has the option to increase its interest in Little Green Pharma to a maximum of 19.03%, subject to a number of conditions, including Australian Government regulatory approvals. Little Green Pharma (www.lgpharma.com.au John McMullen, LGC's CEO, commented; "This will be LGC's first investment into the legalized Medical Cannabis sector in the Asia-Pacific region. This will be an important investment initiative for LGC in the region as Little Green Pharma is one of the few companies in Australia licenced to cultivate and produce Medical Cannabis. Australia has now legalized the use of Medical Cannabis and Little Green Pharma plans to commence production shortly." Fleta Solomon, Little Green Pharma's Managing Director, commented; "We look forward to having LGC on board as a new strategic long-term shareholder in Little Green Pharma. LGC's support and funding will assist in providing the necessary working capital to allow Little Green Pharma to cultivate and produce our product range for Australian patients in the coming months." Binding Term Sheet The binding term sheet between LGC and Little Green Pharma provides that: 1. LGC will subscribe for 2,161,091 shares of Little Green Pharma, representing 4.99% of its issued and outstanding shares, by paying AUD $432,218 and issuing 5,660,000 LGC common shares to Little Green Pharma at a deemed issue price of $0.11 per share. 2. Subject to the issuance by Little Green Pharma of shares to various third parties, LGC will subscribe for a further 752,937 shares of Little Green Pharma for cash consideration of AUD $150,587, so as to maintain its shareholding of 4.99% in Little Green Pharma. 3. Subject to approval by Little Green Pharma in its sole discretion, LGC may further subscribe, at its option, for additional shares of Little Green Pharma in order to increase its shareholding to a maximum of 19.03%. In the event that this option is exercised, LGC will subscribe for a maximum of 4,585,972 shares of Little Green Pharma for maximum cash consideration of AUD $917,194. On September 25, 2017, the Bank of Canada's daily average exchange rate for the Australian dollar was AUD $1.00 = CAD $0.9806. Closing Conditions Closing of the transaction with Little Green Pharma is subject to standard conditions, including the negotiation and signing of a definitive subscription agreement between LGC and Little Green Pharma. LGC cannot give any assurance that the transaction with Little Green Pharma will close in accordance with the terms and conditions of the binding term sheet or at all. Further, LGC cannot proceed with any investment in Little Green Pharma prior to obtaining formal approval from the TSX Venture Exchange with respect thereto. Although LGC has commenced the process for obtaining formal approval from the TSX Venture Exchange, LGC cannot give any assurance that it will be able to obtain such approval. LGC will require the approval of the Australian Government's Office of Drug Control (ODC) in order to increase its interest in Little Green Pharma to more than 4.99% and may require the approval of the Australian Foreign Investment Review Board (FIRB) to increase its interest in Little Green Pharma to more than 15%. Little Green Pharma has agreed to provide all necessary assistance and support to LGC with respect to such government approvals. LGC cannot give any assurance that it will be able to obtain such approvals, to the extent necessary. Little Green Pharma LGC understands that Little Green Parma is a privately-owned company based in Western Australia and that in April 2017, Little Green Pharma was granted one of the few licenses in Australia by the Australian Government's Office of Drug Control (ODC) to cultivate and produce Medicinal Cannabis for Australian patients from June 1, 2017. Little Green Pharma has stated that its goal is to make safe, reliable and cost-effective Medicinal Cannabis products available to Australians through approved medical practitioners, and that it will produce a range of Medical Cannabis preparations with differing cannabinoid profiles from multiple plant varieties. Little Green Pharma has advised LGC that it has an advanced manufacturing technology for producing Medicinal Cannabis for oral administration. Its process ensures high bio-availability of the active cannabinoids, meaning that a therapeutic effect can be achieved with precise dosage control and with significantly lower cannabinoid doses. Little Green Pharma has stated that its manufacturing process can maintain the integrity of CBD-A and THC-A if required, avoiding the carboxylation of important cannabinoids. Preparations will meet strict regulatory standards for medicinal cannabis specifications ensuring a clean, high-quality product. All growing, production and good manufacturing practice is subject to the terms of the Australian federal licence aimed at security and quality assurance by the relevant regulatory bodies. The Australian Medical Cannabis Market Little Green Pharma has advised LGC that Australia passed federal legislation in 2016 aimed at permitting the use of Medicinal Cannabis via a tightly-controlled licensed medical prescription system. In March 2016, The White Paper, entitled Medicinal Cannabis in Australia: Science, Regulation & Industry, was developed by the University of Sydney Business School's Community Placement Program. Its publication followed the news that the Australian Government would shortly allow the cultivation of cannabis in Australia for medical or scientific purposes. As the first-ever White Paper that analyses the medicinal cannabis industry in Australia, the paper examines international experiences and approaches, supply chain economics, quantities of cannabis required and potential regulatory dynamics. It also serves as a framework for the industry to commence engaging key stakeholders such as the Australian Government and the medical community. The University of Sydney summary of the White Paper can be viewed via the below link: hxxp://sydney.edu.au The White paper can be viewed at: hxxp://mgcpharma.com Highlights of the White Paper: Australia would need to produce 8,000 kg of medicinal cannabis per year to service the existing market. Australian market currently estimated to be worth AUD $100 million –AUD $150 million per annum, and is likely to grow significantly in the next decade. Medical Cannabis has the potential to help tens of thousands of patients suffering from a wide range of medical conditions such as Multiple Sclerosis, Epilepsy, Cancer, and Severe and Chronic Pain. Up to 51,000 square metres of greenhouse space - almost three times the size of the Sydney Cricket Ground - would be needed to produce the amount of cannabis required to meet demand. About LGC (hxxp://www.lgc-capi LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services. | cpap man | |
| 26/9/2017 12:40 | TSXV:REG Walter Walcarpets26 Sep '17 - 12:17 - 4 of 4 1 0 John Black was the founder of Antares Minerals and is just performing the same trick he did with them. Should make us a few bob :-) | cpap man | |
| 26/9/2017 07:10 | TSXV:REG www.regulusresources Walter Walcarpets25 Sep '17 - 21:58 - 2 of 3 1 0 this is going to be very big MEGA even! | cpap man | |
| 17/9/2017 16:45 | TSXV:LG "We're ready. We're setting ourselves to be the global leader in medical cannabis," said Dr Thandeka Ruth Kunene, House of Hemp $LG.v $QBA.v | cpap man | |
| 17/9/2017 16:42 | TSXV:LG LGC Capital Ltd. to change stock symbol to "LG" Lgc Capital Ltd (TSXV:QBA) Symbol: TSX-V: QBA MONTREAL, Sept. 14, 2017 /CNW Telbec/ - LGC Capital Ltd. (TSXV: QBA) ("LGC") announces that its stock symbol will change to "LG" effective at the opening of the markets on Monday, September 18, 2017. Until that time, LGC's shares will continue to trade under the current stock symbol "QBA". LGC's shares are listed on the TSX Venture Exchange. About LGC (hxxp://www.lgc-capi LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital has now entered into the agricultural space and the medical cannabis sector in southern Africa through its new joint venture with AfriAg and is seeking new investments opportunities in this sector. | cpap man | |
| 02/9/2017 08:35 | TSXV:QBA chanlfc1 Sep '17 - 22:25 - 24 of 24 1 0 I hear newsflow about to start... it will get into the $'s for sure.maybe not in 2017 but surely will in 2018. | cpap man | |
| 01/9/2017 18:30 | TSXV:QBA TSXV:QBA are performing well again so far today! | cpap man | |
| 31/8/2017 15:00 | TSXV:QBA chanlfc31 Aug '17 - 14:47 - 22 of 22 1 0 QBA $0.12 - MACAP: 27 mill shares in issue : 234,201,810 ACB $2.14 - MCAP : 913 mill shares in issue : 367,046,893 APH $6.01 - MCAP : 834 mill shares in issue : 138,819,504 APH $8.83 - MCAP : 1,509,653,886 mill shares in issue : 170,968,730 Do the maths..... All above companies in cannabis growth., we have fingers in many pies including massive Oil production Q1 2018. It will easly go into $$. | cpap man |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
